Sathyanarayanan Sriram 4
4 · Codiak BioSciences, Inc. · Filed Jan 23, 2023
Insider Transaction Report
Form 4
Sathyanarayanan Sriram
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2023-01-19+2,834→ 2,834 total - Sale
Common Stock
2023-01-20$0.58/sh−1,082$622→ 1,752 total - Exercise/Conversion
Restricted Stock Units
2023-01-19−2,834→ 5,666 total→ Common Stock (2,834 underlying)
Footnotes (4)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
- [F3]Each RSU represents a contingent right to receive one share of common stock.
- [F4]On January 19, 2022, the reporting person was granted 8,500 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date.